论文部分内容阅读
苯并吡喃类新化合物Ｓ１０３的药理作用初步研究结果表明：该化合物有较好的血管舒张活性，能浓度依赖性地抑制由ＫＣｌ和去甲肾上腺素刺激引起的大鼠胸主动脉条的收缩，对低Ｋ＋刺激引起收缩有较好的舒张作用（ＩＣ５０为０．４２±０．０７μｍｏｌ／Ｌ），其舒张作用被四乙铵和格列苯脲所拮抗；Ｓ１０３浓度依赖地抑制大鼠门静脉自发活动的收缩幅度；还能增加预先负载８６Ｒｂ＋的大鼠胸主动脉条的８６Ｒｂ＋外流；其作用特点和吡那地尔相似，表现出ＡＴＰ敏感钾通道开放剂的特证。实验结果提示Ｓ１０３是一个新的ＡＴＰ敏感钾通道开放剂。
The preliminary pharmacological effects of benzopyran novel compound S103 showed that the compound has good vasodilator activity and can inhibit the contraction of rat thoracic aortic strips in a concentration-dependent manner by KCl and norepinephrine stimulation , With a good relaxation effect on contractility induced by low K + stimulation (IC50 0.42 ± 0.07μmol / L), and its diastolic action was antagonized by tetraethylammonium and glibenclamide. S103 inhibited rat portal vein in a concentration-dependent manner Spontaneous contraction; and also increased 86Rb + efflux of the rat thoracic aortic strips preloaded with 86Rb +; its action profile is similar to pinacidil and evidence of ATP-sensitive potassium channel openers. The results suggest that S103 is a new ATP-sensitive potassium channel opener.